Patrick Weydt

Motor phenotypes of amyotrophic lateral sclerosis – a three-determinant anatomical classification based on the region of onset, propagation of motor symptoms, and the degree of upper and lower motor neuron dysfunction

Targeted Proteomics upon Treatment with Tofersen Identifies Novel Response Markers for Superoxide Dismutase 1‐Linked Amyotrophic Lateral Sclerosis

Self-assessment of amyotrophic lateral sclerosis functional rating scale on the patient’s smartphone proves to be non-inferior to clinic data capture

Serum Cardiac Troponin T Levels as a Therapy Response Marker in Tofersen‐Treated <scp>ALS</scp>

Combination of Serum Neurofilament Light Chain and Serum Cardiac Troponin T as Biomarkers Improves Diagnostic Accuracy in Amyotrophic Lateral Sclerosis

Motor phenotypes and neurofilament light chain in genetic amyotrophic lateral sclerosis—results from a multicenter screening program

Provision, cough efficacy and treatment satisfaction of mechanical insufflation-exsufflation in a large multicenter cohort of patients with amyotrophic lateral sclerosis

Dextromethorphan/quinidine (DMQ) for reducing bulbar symptoms in amyotrophic lateral sclerosis – assessment of treatment experience in a multicenter study

Plasma extracellular vesicle tau and TDP-43 as diagnostic biomarkers in FTD and ALS

Effects of tofersen treatment in patients with SOD1-ALS in a “real-world” setting – a 12-month multicenter cohort study from the German early access program

The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biology

Serum neurofilament light chain in distinct phenotypes of amyotrophic lateral sclerosis: A longitudinal, multicenter study

Clinical and patient‐reported outcomes and neurofilament response during tofersen treatment in <i>SOD1</i>‐related <scp>ALS</scp>—A multicenter observational study over 18 months

Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial

<i>SOD1</i> gene screening in ALS – frequency of mutations, patients’ attitudes to genetic information and transition to tofersen treatment in a multi-center program

Neurofilament light‐chain response during therapy with antisense oligonucleotide tofersen in <scp>SOD1</scp>‐related <scp>ALS</scp>: Treatment experience in clinical practice

Performance of serum neurofilament light chain in a wide spectrum of clinical courses of amyotrophic lateral sclerosis—a cross‐sectional multicenter study

Remote digital assessment of amyotrophic lateral sclerosis functional rating scale – a multicenter observational study

Use and subjective experience of the impact of motor-assisted movement exercisers in people with amyotrophic lateral sclerosis: a multicenter observational study

Proteomics in cerebrospinal fluid and spinal cord suggests UCHL1, MAP2 and GPNMB as biomarkers and underpins importance of transcriptional pathways in amyotrophic lateral sclerosis

Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase

Comprehensive analysis of the mutation spectrum in 301 German ALS families

Provision of assistive technology devices among people with ALS in Germany: a platform-case management approach

The metabolic and endocrine characteristics in spinal and bulbar muscular atrophy

Safety, tolerability, and preliminary efficacy of an IGF-1 mimetic in patients with spinal and bulbar muscular atrophy: a randomised, placebo-controlled trial

Hot-spot KIF5A mutations cause familial ALS

Targeting Neuroinflammation to Treat Alzheimer’s Disease

July 2017 ENCALS statement on edaravone

Ribosomal transcription is regulated by PGC-1alpha and disturbed in Huntington’s disease

Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia